Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines (Q73905123)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

M Taron

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

C Plasencia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

A Abad

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

C Martin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M Guillot

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 May 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

139-147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10857993%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1006325929424

7 November 2019

exact match

0 references

cites work

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

12 December 2020

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

1 reference

12 December 2020

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

1 reference

12 December 2020

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

1 reference

12 December 2020

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells

1 reference

12 December 2020

Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors

1 reference

12 December 2020

Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro

1 reference

12 December 2020

Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells

1 reference

12 December 2020

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

12 December 2020

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line

1 reference

12 December 2020

Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide

1 reference

12 December 2020

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue

1 reference

12 December 2020

Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines

1 reference

12 December 2020

Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function

1 reference

12 December 2020

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

12 December 2020

Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin

1 reference

12 December 2020

Action of camptothecin on mammalian cells in culture

1 reference

12 December 2020

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

12 December 2020

p53 and chemosensitivity.

1 reference

12 December 2020

Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells

1 reference

12 December 2020

Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.

1 reference

12 December 2020

The current status of camptothecin analogues as antitumor agents

1 reference

12 December 2020

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

12 December 2020

Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells

1 reference

12 December 2020

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

1 reference

12 December 2020

Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture

1 reference

12 December 2020

Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.

1 reference

12 December 2020

Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.

1 reference

12 December 2020

Participation of p53 protein in the cellular response to DNA damage

1 reference

12 December 2020

Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II)

1 reference

12 December 2020

Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: implications for gene therapy

1 reference

12 December 2020

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

12 December 2020

Biochemical and cellular determinants of bleomycin cytotoxicity

1 reference

12 December 2020

Topoisomerase inhibitors. A review of their therapeutic potential in cancer

1 reference

12 December 2020

Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei

1 reference

12 December 2020

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

1 reference

12 December 2020

DNA double-strand breaks and alkali-labile bonds produced by bleomycin

1 reference

12 December 2020

Arrest of Chinese hamster cells in G 2 following treatment with the anti-tumor drug bleomycin

1 reference

12 December 2020

Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme

1 reference

12 December 2020

Effects of Taxotere on murine and human tumor cell lines

1 reference

12 December 2020

Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity

1 reference

12 December 2020

Cell cycle stage-dependent induction of G2 phase arrest by different antitumor agents

1 reference

12 December 2020

Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons

1 reference

12 December 2020

Evidence for a second cell cycle block at G2/M by p53.

1 reference

12 December 2020

Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process

1 reference

12 December 2020

Current perspectives on camptothecins in cancer treatment

1 reference

12 December 2020

The significance of the sequence of administration of topotecan and etoposide

1 reference

12 December 2020

The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B

1 reference

12 December 2020

In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells.

1 reference

12 December 2020